REDX
PHARMA PLC
("Redx"
or the "Company")
Result of
General Meeting and Cancellation of Admission to Trading on
AIM
Alderley Park, UK, 19 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company
focused on discovering and developing novel, small molecule,
targeted therapeutics for the treatment of fibrotic disease and
cancer announces that, at the general meeting of the Company held
earlier today (the "General
Meeting"), all resolutions put to the Company's shareholders
("Shareholders") were duly
passed on a poll.
The table below sets out the details
of the votes put to Shareholders:
|
Resolution Number
(*indicates special
resolution)
|
Resolution Name
|
Votes
For
|
Votes
Against
|
Votes
Withheld*
|
Total
Votes Cast (excl. withheld)
|
|
No. of
shares
|
% of
shares voted
|
No. of
shares
|
% of
shares voted
|
No. of
shares
|
|
1*
|
Cancellation Resolution
|
351,522,100
|
99.75%
|
882,304
|
0.25%
|
4,291
|
352,404,404
|
|
2*
|
Re-registration Resolution and Adoption of New Articles of
Association
|
351,522,100
|
99.75%
|
882,304
|
0.25%
|
4,291
|
352,404,404
|
*A
vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes 'For' or
'Against'
The full text of the resolutions
proposed and passed at the General Meeting can be found in the
circular containing, inter
alia, the Notice of General Meeting, which was published and
posted to Shareholders on 2 April 2024 and is available on the
Company's website www.redxpharma.com
(the "Circular").
AIM
Delisting
Following approval by Shareholders
at the General Meeting, the admission of the ordinary shares of 1
pence each in the capital of the Company ("Ordinary Shares") to trading on AIM
will be cancelled (the "AIM
Delisting"). The AIM Delisting is expected to take place at
7:00 a.m. on 1 May 2024 and, accordingly, the last day of dealings
in Ordinary Shares on AIM is expected to be 30 April
2024.
Matched Bargain Facility
It remains the Company's intention
to provide a matched bargain facility to assist Shareholders
wishing to trade in Ordinary Shares following the AIM Delisting.
Further details with respect to the matched bargain facility, to be
provided by J P Jenkins, will be made available in due course on
the Company's website www.redxpharma.com.
Capitalised terms used but not
defined in this announcement shall have the same meaning given to
such terms in the Circular.
|
For
further information, please contact:
|
|
|
|
|
Redx Pharma Plc
UK
Headquarters
Caitlin Pearson, Head of
Communications
ir@redxpharma.com
|
T: +44 (0)1625 469 918
|
|
SPARK Advisory Partners (Nominated Adviser)
|
T: +44 (0)203 368 3550
|
|
Matt Davis/Adam Dawes
|
|
|
|
|
|
Panmure Gordon (UK) Limited (Broker)
|
T: +44 (0)207 886 2500
|
|
Rupert Dearden/Freddy Crossley/Emma
Earl
|
|
|
|
|
|
FTI
Consulting
|
T: +44 (0)203 727 1000
|
|
Simon Conway/Ciara Martin
|
|
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a
clinical-stage biotechnology company focused on the discovery and
development of novel, small molecule, targeted therapeutics for the
treatment of fibrotic disease, cancer and the emerging area of
cancer-associated fibrosis. Redx aims to progress its programmes to
clinical proof of concept before evaluating options for further
development and potential value creation. The Company expects a
number of data points during 2024 including from lead fibrosis
product candidate, the selective ROCK2 inhibitor, zelasudil
(RXC007), in development for interstitial lung disease and
currently undertaking a Phase 2a trial for idiopathic pulmonary
fibrosis (IPF). The Company's second fibrosis
candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is in Phase 1
development and is expected to report healthy volunteer data; and
Redx's lead oncology product candidate, the Porcupine inhibitor
zamaporvint (RXC004), being developed as a targeted treatment for
Wnt-ligand dependent cancers, is expected to report anti-PD-1
combination Phase 2 data, following which Redx will seek a partner
for ongoing development.
The Company has a strong track
record of discovering new drug candidates through its core
strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated
therapeutics against biologically or clinically validated targets.
The Company's accomplishments are evidenced not only by its
wholly-owned clinical-stage product candidates and discovery
pipeline, but also by its strategic transactions, which includes
the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent
or reversible BTK inhibitor now approved by the US FDA, and
transactions with both AstraZeneca and Jazz
Pharmaceuticals.
To subscribe to Email Alerts from
Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.